Regulatory -
FDA approves polatuzumab vedotin-piiq for diffuse large B-cell lymphoma
FDA
- FDA grants accelerated approval of Polivy to Genentech. One more approval is always a good day for ADCs in general
Manuscripts -
A Physical Organic Approach to Tuning Reagents for Selective and Stable Methionine Bioconjugation
ChemRxiv
- Cysteine conjugation is now well established for ADCs but can methionines be used to accomplish site-specific conjugation as well. Look out THIOmab
Boronic acids as building blocks for the construction of therapeutically useful bioconjugates
Royal Society of Chemistry
- A nice review article about using boronic acids to find new bioconjugate targets
Considerations for the Design of Antibody-Based Therapeutics
Journal of Pharmaceutical Sciences
- Its easy to forget that every ADC is based on the mAb. This is a nice review about the challenges and intricacies of mAb engineering
Clinical Results -
Positive results from RC48 Clinical Trial in HER2-Positive Metastatic or Unresectable Urothelial Cancer
Biospectrum Asia
- Phase II clincal results showing that HER2 is not limited to breast cancer. IND to be filed later this year
-----------------------------
Thats it for today. There are always more coming down the pike. Is there something I missed? Contact me. [email protected]
No comments:
Post a Comment